CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tikcro Technologies, Ltd. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tikcro Technologies, Ltd.
HANASI WEIZMAN 126
Phone: +972 36962121p:+972 36962121 NESS-ZIONA, 7403630  Israel Ticker: TIKRFTIKRF

This company ceased filing statements with the SEC on 4/29/2021.
On 4/29/2021, Tikcro Technologies Ltd.’s Shareholders approved the Board of Directors proposal to Voluntarily Liquidate the Company. Mr. Ran Gurit was appointed as the Liquidation Trustee.
This company is no longer actively traded on any major stock exchange.

Business Summary
Tikcro Technologies Ltd. (Tikcro) provides funding for early-stage biotechnology projects with a focus on oncology. The Company provides funding for early-stage biotechnology projects originating in Israeli academic centers. The Company's product candidate antibodies focuses on blocking the ligand/receptor linkage of certain biological pathways, specifically antibodies that block anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1), and by blocking these pathways to prevent the inhibition of patients' self immune system and its ability to attack cancerous cells. The Company focuses on antibody drug-candidates that block the binding surface domain and do not block adjacent domains. The Company's project focuses on the immune system pathways, which include CTLA-4 and its binding group of ligands; PD-1 and ligands PDL-1 and PDL-2, and T cell immunoreceptor with Ig and ITIM domains (TIGIT) and its binding group of ligands.
(Source: 20-F)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202012/31/2019YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board IzhakTamir 67 12/1/2007 1/1/2000
Chief Executive Officer AvivBoim 54 10/1/2010 1/1/2008
Director DrorMelamed 59 1/1/2019 1/1/2019
3 additional Officers and Directors records available in full report.

General Information
Number of Employees: 2 (As of 12/31/2011)
Outstanding Shares: 9,878,861 (As of 12/31/2020)
Shareholders: 53
Stock Exchange: OTC
Fax Number: +972 97442446
Email Address: info@tiogatech.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 30, 2023